A Phase II Single Arm, Multi-centre Study of Bevacizumab (Avastin®) Pre- and Post-transarterial Chemoembolisation (TACE) Treatment for Localized Unresectable Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase II Single Arm, Multi-centre Study of Bevacizumab (Avastin®) Pre- and Post-transarterial Chemoembolisation (TACE) Treatment for Localized Unresectable Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 10 Aug 2012 Actual patient number changed from 25 to 29 as reported by ClinicalTrials.gov record.
    • 10 Aug 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov record.
    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top